MedTrace Logo

Predictive Factors for Response to New Oral Anticoagulants in the Treatment of Non-valvular Atrial Fibrillation..

NCT04297150 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 700

Last updated 2023-06-06

No results posted yet for this study

Summary

Post-authorization observational, prospective, follow-up study of a cohort of patients with non-valvular atrial fibrillation who are treated with direct oral anticoagulants (DOACs) to evaluate the clinical course (occurrence of stroke, major bleeding and mortality) and its correlation with clinical, pharmacokinetic (plasma concentrations), pharmacodynamic (haemostatic) and pharmacogenetic factors.

Conditions

Interventions

DRUG

Apixaban

Drug indicated for the treatment of NVAF

DRUG

Edoxaban

Drug indicated for the treatment of NVAF

DRUG

Rivaroxaban

Drug indicated for the treatment of NVAF

DRUG

Dabigatran

Drug indicated for the treatment of NVAF

Sponsors & Collaborators

  • Fundación de Investigación Biomédica - Hospital Universitario de La Princesa

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-18
Primary Completion
2023-09-30
Completion
2023-09-30

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04297150 on ClinicalTrials.gov